

ABIVAX S.A.

ISIN: FR0012333284 WKN: - Asset Class: **Stock**

Company

2022/05/18 13:56:16



Price

17.12

EUR

Difference



2.76%(0.46)



Contact Details

ABIVAX SA Tel: 33-1-53-83-08-41
-- Fax: --
5, rue de la Baume Web: <http://www.abivax.com>
75008 Paris E-mail: info@abivax.com

Company Profile

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	74,713,000		36,544,000		17,092,000	
Common stock capital		168,000		143,000		122,000
Fixed assets	35,652,000		34,754,000		34,636,000	
Equity capital of a company		28,774,000		4,673,000		11,781,000
Cash and cash equivalents	60,695,000		29,296,000		9,765,000	
Accrued liabilities		98,000		1,000		0
Other assets	-		-		-	
Current liabilities		31,521,000		24,944,000		15,749,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		50,070,000		41,681,000		24,198,000
Different income		-		-		-
Other liabilities		6,837,000		13,235,000		6,816,000
Total assets	110,365,000	110,365,000	71,298,000	71,298,000	51,728,000	51,728,000

Balance notes

	2021	2020	2019
Accounting standard	-	-	-
Employees	26	27	26
Equity ratio	26.07%	6.55%	22.77%
Debt-equity ratio	283.56%	1,425.74%	339.08%

Others

	2021	2020	2019
Tax Expense Rate	9.23%	6.42%	12.20%

Income statement

	2021	2020	2019
Turnover	0	0	0
Net income	-41,357,000	-37,551,000	-30,634,000
EBIT	-42,435,000	-37,808,000	-33,259,000
Operating income before taxes	-45,561,000	-40,126,000	-34,891,000
Cash Flow	-45,657,000	-29,823,000	-27,473,000
Net interest income	-3,126,000	-2,318,000	-1,632,000
Research and development expenses	47,202,000	34,526,000	29,007,000
Income taxes	-4,204,000	-2,575,000	-4,257,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	0	0	0

Board of Directors

Philippe Pouletty	Chairman of Supervisory Board
Antonino Ligresti	Member of Supervisory Board
Carol Brosgart	Member of Supervisory Board
Christian Pierret	Member of Supervisory Board
Kinam Hong	Member of Supervisory Board
Corinna Zur Bonsen-Thomas	Member of Supervisory Board
Jean-Jacques Bertrand	Member of Supervisory Board
Joy Amundson	Member of Supervisory Board

Members of Management Board